Antidepressant withdrawal is rare, study finds. Here are the most common symptoms
The study, published in the journal JAMA Psychiatry, is the largest review to date on antidepressant withdrawal symptoms, according to the researchers from the United Kingdom.
It sought to understand what happens when people stop taking antidepressants, and to identify which symptoms come from discontinuing medication and which could reflect a potential relapse of depression or other mental health issues.
'Our work finds that most people do not experience severe withdrawal, in terms of additional symptoms,' Dr Sameer Jauhar, the study's lead author and a researcher at Imperial College London, said in a statement.
The review included 50 randomised controlled trials – which are considered the gold standard in medical research – spanning about 17,800 people.
On average, people who stopped taking antidepressants experienced symptoms such as dizziness, nausea, vertigo, and nervousness in the first two weeks.
But most people had few enough symptoms that they were considered 'below the cutoff' for clinical withdrawal, the study found.
People's moods also did not appear to get worse as a result of discontinuing their medicine, meaning it could instead be a sign that their depression is coming back, researchers said.
Related
Antidepressant prescriptions have increased among young French people since 2019, report finds
The findings contradict another study published earlier this year that found antidepressant withdrawal symptoms were 'common, and severe and prolonged' for many patients.
But Katharina Domschke, chair of the psychiatry and psychotherapy department at the University of Freiburg in Germany, said that study was 'methodologically much weaker' because it only included 310 patients and had a higher risk of bias in the results.
The latest analysis is 'extremely welcome in terms of helping to destigmatise antidepressants,' added Domschke, who was not involved with the report.
The study included several types of antidepressants, including agomelatine, vortioxetine, selective serotonin reuptake inhibitors (SSRIs) such as escitalopram, sertraline and paroxetine, and serotonin-norepinephrine reuptake inhibitors (SNRIs) like venlafaxine and duloxetine.
Researchers tracked the number of symptoms that people experienced on a 43-item scale, comparing those who went off antidepressants against those taking placebos, or dummy treatments.
Overall, patients who stopped antidepressants experienced one extra symptom – such as nausea or vertigo – than people who stopped placebos. For example, 20 per cent of people who stopped taking venlafaxine suffered from dizziness, compared with just 1.8 per cent of those on placebos.
Related
Pills or paintings? Swiss town lets doctors prescribe free museum visits as art therapy
Different antidepressants also came with different severity and length of symptoms. People who went off of desvenlafaxine experienced the most symptoms, while patients who stopped vortioxetine were fairly similar to those who took placebo medicines.
The review has some limitations. Most of the studies followed people for up to two weeks after they stopped taking antidepressants, making it difficult to draw conclusions about long-term effects.
'We still need more data on long-term users, individual vulnerability, and best practices for discontinuation,' Dr Christiaan Vinkers, a psychiatrist and stress researcher at Amsterdam University Medical Center who was not involved with the study, said in a statement.
For now, Vinkers said, "the findings promote a more balanced and science-based understanding of antidepressant discontinuation".
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Aitana Bonmati interview: ‘I found myself in a situation of suffering. You feel alone'
It was 7am on Thursday, June 26 when Aitana Bonmati began to feel unwell. She had been in Madrid for four days with the Spanish national team preparing for a match against Japan and the European Championship to follow. Like the other players, she was up and getting ready for an earlier-than-usual training session in an attempt to avoid the intense heat. 'That's when I started to feel very ill,' Bonmati says, speaking to The Athletic in Lausanne, Switzerland, two days before Spain's Euro 2025 quarter-final against the hosts. 'I had a bad headache, which surprised me because it was constant and wouldn't go away. 'I was like that until Friday at noon, when the doctor told me to go to the hospital because something was wrong. He wanted to rule out anything more serious than a simple cold or a mild illness. There, they did a CT scan and everything came back fine. Then they did a blood test and everything came back fine. Then they did a lumbar puncture, which is where they found I had viral meningitis.' Bonmati, the reigning two-time Ballon d'Or winner, was lying on her hospital bed when the doctor delivered the news. Fortunately, it was not bacterial meningitis, which takes much longer to recover from. That evening, her Spain team-mates were in action against Japan in their final game before departing, three days later, for the Euros. During the match, the midfielder posted a picture from her hospital bed, with the game on the television in front of her and an emoji of an arm flexing its biceps, as if to say she felt strong. 'She is a very important player for us, we are going to wait for her until the end,' Spain head coach Montse Tome said after the match. At the hospital, the 27-year-old continued to talk with doctors. 'They explained what meningitis meant. I also started looking it up on the internet because meningitis is something you may have heard of but don't really know what it is.' Everything pointed to the player missing the first matches of the Euros. Alarm bells rang. 'The diagnosis was that I might be unwell for five to 10 days, and then I might have some symptoms,' she adds. 'At that point, I didn't get too worked up. I was coming to terms with the fact that I had something that I didn't even know what it was. I accepted it and carried on. 'I was away from my home environment because I was with the national team and at that precise moment I was alone. Then a lifelong friend of mine, Maria, came. She came on Saturday and stayed until Sunday. She slept in my room with me. I didn't have any other visitors because I didn't want to bring people over if I didn't know when I was going to be discharged. 'I found myself in a situation of suffering, because when something happens to you that you don't understand where it comes from, you feel a little alone because you're not in your close environment. But I'm very grateful to Maria for always supporting me. It's good to have people like that around. 'At that moment, I wasn't thinking about whether I would be able to come back or not because I was confident I would get through it. At no point did I think I was out of the Euros. 'I took it easy and I didn't get carried away. All the work I do every day to take care of myself: to eat well, to be healthy, not to smoke, not to drink alcohol, basic things like that, to play sport, obviously… I think your body remembers how you treat it. I'm not a doctor, but I think that helped me.' Three days after being admitted to the hospital, Bonmati was discharged. The next day, she travelled to Lausanne, Spain's base camp, to rejoin her team-mates. 'Fortunately, I was only really unwell for two or three days, but then I made a radical change for the better,' she says. 'I didn't have a gradual progression; I went from feeling very bad to feeling fine.' At a press conference prior to Spain's opening match against Portugal, Tome said the player's progress was positive, that she had shown a very good attitude but that 'Aitana had to be slowed down'. 'From then on, I wanted to speed things up because I felt fine and had no symptoms whatsoever,' Bonmati says. 'I wanted to start training, even if it was gradually. I wanted to get my body working. 'It's part of who I am. I don't want to waste a single day. If I'm 100 per cent fit to be there, I'll be there. I don't like wasting days. Here, a day lost is a day less. On the Sunday when I was discharged, I trained in Las Rozas (Madrid). I went to the gym and moved around a bit. I had been lying down for three or four days without doing anything. 'On Monday morning, I trained again at the gym a little harder, starting to try some jumps to see how the pressure in my head felt. Everything went well. I arrived in Lausanne and started training the next day. The group was already training, and I trained separately. 'Obviously, I would like the progress to have been faster. I suppose everyone here is aware and takes some responsibility because it's not just any illness. I understand that. But I felt fine, I wanted to start feeling part of the group. I had already felt out of the group for a few days. If I felt fine, why couldn't I come back sooner? That was the frustration I felt. Looking at it in perspective, I suppose you have to understand everyone's opinion. 'I don't consider myself a player who finds it difficult to get into shape; I had a lot of confidence in my body and my physical condition. It has been a learning process. Life sometimes throws you these setbacks that make you deal with certain situations you're not used to. 'I wanted to be on the pitch, I wanted to feel good. I wanted to enjoy and I haven't enjoyed what's happened to me very much because I've had to deal with this frustration.' Remarkably, six days after the diagnosis, Bonmati came off the bench with nine minutes remaining of the 5-0 win over Portugal. She had spent the entire match standing in the technical area or by the bench, waving her arms as she always does when she plays to communicate with her team-mates. Like a police officer, as her father always jokes. 'On the one hand, I felt proud to have been part of the match and to have been able to play for a few minutes,' she says. 'On the other, I felt frustrated… But obviously, with what had happened to me, I had to be more grateful than frustrated.' Against Belgium, all eyes were on whether she would return to the starting XI or not. Tome decided to go with Vicky Lopez again. 'It was something that was discussed internally,' Bonmati says. 'We wanted to take good care of my physical condition so I would be in the best possible shape for the most important part, which is now (the knockout stages). Having been in the hospital, I had to respect the timeframe; they treated it as if it were an injury. When a player is injured, they're not going to exploit her. 'Sometimes you have to reach agreements or understand the other person's point of view. As a player, I was frustrated to see the process taking so long, but I know it was done with my best interests in their minds.' She made her first start of the Euros against Italy in the final group match — a 3-1 win — and is now able to think again about adding the one title that is missing from her collection. 'What we have done so far is very good and it's a good platform to face what's coming,' she says. 'But now we have decisive, do-or-die matches against tough opponents. Next up is Switzerland, the host nation. We're back in the quarter-finals against the host nation — in 2022, it was England. Now it's Switzerland. 'They've had a great tournament and, as the hosts, there are things that work in their favour. The crowd will be behind them. But it's also cool as a player to experience these moments.' Which other teams has she been impressed by? 'I really like France and Germany,' she says. 'France are a different team from what we've seen in recent years. They're very young with a lot of talent and versatility. They have a rich bench to change things up and energise the games. They have some very good players, such as Delphine Cascarino. 'Then there is Germany. The other day, they conceded four goals and had a player sent off, but they started the game (against Sweden) with a brutal level of intensity. In fact, we commented with some players that they were flying. I'm really liking (Klara) Buhl, I think she's at a very good level. (Jule) Brand too.' Spain are based in Lausanne, on the shores of Lake Geneva, and the team are making the most of what Switzerland has to offer. 'It's one of my favourite countries,' she says. 'I came here years ago on a trip, in winter. It's a country that transports you to tranquillity. It seems that everywhere you go is like a postcard landscape. Everywhere. 'Being in a city like Lausanne, with the hotel in the centre, gives us freedom to visit places. The other day we had a day off and we all did what we wanted. We went on an excursion I organised to some mountains nearby, on a rack railway, with spectacular views. It's all about breathing fresh air and tranquillity all the time. 'It's something that's sometimes lacking in Catalonia, which also has stunning landscapes, but in the area where I live, it's not the same. Switzerland is an amazing country.' But now, with the quarter-finals under way, it is time for business. 'I'm approaching this final stretch with a lot of energy, enthusiasm and excitement, eager to play three good matches,' Bonmati adds. 'Let's hope it's three, because that would be good news. And I'm feeling very well.' This article originally appeared in The Athletic. Barcelona, Spain, Premier League, La Liga, Women's Soccer, Women's Euros 2025 The Athletic Media Company
Yahoo
5 minutes ago
- Yahoo
Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer
Comprehensive analysis of the NTM therapeutics market: Overview of disease, epidemiology, treatment options, and forecast from 2023-2033 for 7 major markets. Insights include pipeline trends, market drivers, competitive landscape, and strategies for growth and investment in the NTM market. Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The "Nontuberculous Mycobacteria (NTM): Opportunity Assessment and Forecast" report has been added to report provides an assessment of the NTM therapeutics market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market refers to infection with a group of bacteria within the Mycobacterium genus, which excludes Mycobacterium tuberculosis (tuberculosis) and Mycobacterium leprae (leprosy). NTM infections are noncontagious, opportunistic infections that cause a wide range of clinical disease in patients with pre-existing health conditions or compromised immune systems.). In terms of global burden, NTM lung disease is relatively uncommon. It is suggested that host defense mechanisms in most healthy individuals are sufficient to prevent or suppress NTM infection. Patients who develop NTM lung disease likely have susceptibility factors such as pre-existing comorbidities that make them vulnerable to these Highlights Report deliverables include a Pdf report and an Excel-based forecast model Forecast includes the 7 major markets (7MM) Forecast covers the period 2023-2033 Scope Overview of NTM, including classification, epidemiology, diagnostic and treatment paradigms. Annualized NTM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include assessment of marketed therapies and pipeline agents, unmet needs, pipeline assessment and market outlook for the US, 5EU, and Japan over the 10-year forecast period. Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. Analysis of the current and future market competition in the 7MM NTM therapeutics market. Insightful review of the key industry drivers and barriers. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines. Develop business strategies by understanding the trends shaping and driving the 7MM NTM therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NTM therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Key Topics Covered: 1. Preface1.1. Contents1.2. Abbreviations1.3. Related Reports2. Executive Summary3. Disease Overview3.1. Overview of NTM3.2. NTM Market SWOT Analysis3.3. Classification of NTM3.4. NTM Risk Factors4. Epidemiology4.1. Diagnosed Incident Cases NTM, N, Both Sexes, 2023-334.2. Diagnosed Prevalent Cases of NTM, Both Sexes, N, 2023-334.3. Diagnosed Incident Cases of NTM, PNTM, and DNTM, Both Sexes, N, 20234.4. Diagnosed Prevalent Cases of NTM, PNTM, and DNTM, Both Sexes, N, 20234.5. Sources and Methodology for Diagnosed Incident Cases of NTM, PNTM, and DNTM4.6. Sources and Methodology for Diagnosed Prevalent Cases of NTM, PNTM and DNTM4.7. Sources and Methodology for Diagnosed Incident and Prevalent Cases of NTM4.8. Sources and Methodology for Diagnosed Incident and Prevalent Cases of PNTM4.9. Sources and Methodology for Diagnosed Incident and Prevalent Cases of DNTM5. Current Treatment Options5.1. PNTM Diagnostic Paradigm5.2. Treatment Paradigm5.3. Current Treatment Options6. Unmet Needs and Opportunities6.1. Unmet Needs in NTM6.2. New Therapeutic Options with Improved Efficacy6.3. Improved Diagnostic Methods6.4. Improved Clinical Trials7. R&D Strategies7.1. Trends in Clinical Trial Design in NTM7.2. Trends in Deal-Making in NTM8. Pipeline Assessment8.1. NTM Pipeline Overview8.2. Late-Stage Pipeline Products for NTM8.3. NTM Clinical Trials (Phase II/III) Overview9. Market Outlook9.1. NTM Market Forecast9.2. PNTM Market Forecast9.3. DNTM Market Forecast9.4. Market Drivers and Barriers10. Appendix Competitive Landscape Janssen Novartis AG Meiji Seika Pharma Co Ltd Insmed Inc Daiichi Sankyo Co Ltd MannKind Corp Paratek Pharmaecuticals Inc Nobelpharma Co Ltd GlaxoSmithKline AG Pfizer For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
6 minutes ago
- Medscape
Rapid Review: Exocrine Pancreatic Insufficiency (EPI)
While historically underdiagnosed, increased awareness and improved diagnostic strategies for exocrine pancreatic insufficiency (EPI) have helped identify patients earlier, thus facilitating more effective management. However, despite advances in treatment modalities, patient outcomes vary considerably due to differences in individual physiology, adherence to treatment regimens, and concurrent health issues. Efforts to address these disparities focus increasingly on personalized medicine, emphasizing the integration of tailored nutritional strategies, patient education, and multidisciplinary care teams to improve patient outcomes comprehensively. Recent guidelines advocate for the prompt initiation of PERT as soon as EPI is diagnosed. Additionally, a multidisciplinary evaluation to assess further nutritional needs and coordination with endocrinologists for the evaluation and treatment of diabetes is also warranted. Untreated EPI can impair growth in pediatric patients, and is associated with a number of clinical symptoms including gastrointestinal effects, osteoporosis, sarcopenia, coagulopathy, neuropathy, and other sequelae related to nutrient deficiency. Although other tests can help in certain cases, EPI can be sufficiently diagnosed with a validated pancreatic function test, and awaiting further confirmatory information such as severe clinical symptoms, positive imaging findings, or documented nutritional deficiencies is not necessary. Learn more about management approaches for EPI. Digestion of fat is a central function of the pancreas, with dysfunction causing deficiency in fat soluble essential vitamins. Although the American Gastroenterological Association (AGA) guidelines recommend a low-to-moderate-fat diet for patients with EPI, they specifically recommend against a very-low fat diet as this can exacerbate deficiencies. Further, meals should be more frequent and smaller, and vitamin and mineral deficiencies should be screened for at diagnosis and annually thereafter. Learn more about diet in EPI. Although fecal fat testing is considered the gold-standard for assessing fecal fat malabsorption, which is a measure of pancreatic dysfunction, it has low specificity for EPI since other diseases can present with steatorrhea. The AGA notes that fecal fat testing is 'rarely needed', it is burdensome (requires a 72 hour stool collection), and can only be done when the patient is on a high-fat diet. Additionally, fecal fat tests are known to be susceptible to false positive results in patients with diarrhea, which is a common symptom of EPI. The AGA recommends fecal elastase as the best test for initial screening, although fecal fat may be useful in cases with inconclusive clinical features and imaging. Learn more about pancreatic function tests. The AGA Clinical Practice Update emphasizes that while cross-sectional imaging — such as CT, MRI, and endoscopic ultrasound — cannot directly diagnose EPI, it plays an essential role in identifying benign and malignant pancreatic diseases that may underlie or contribute to exocrine insufficiency. Imaging can reveal features like advanced calcific chronic pancreatitis, ductal changes, or significant pancreatic atrophy, which correlate with the presence of EPI. However, moderate changes in imaging do not reliably correlate with EPI, and normal imaging is associated with its absence. Although advanced tools like secretin-enhanced MRCP or elastography show promise, current imaging lacks sufficient accuracy to predict EPI on its own. Therefore, imaging should be viewed as a complementary tool in the diagnostic process, providing context about pancreatic structure rather than functional status. For dosing of PERT, the AGA has specific recommendations dependent on fat content of meals and current symptom profile, not imaging findings. Learn more about the multidisciplinary workup for patients with EPI. The latest AGA guidelines emphasize the importance of regular and comprehensive monitoring of nutritional status in all patients with EPI, including regular DEXA scans every 1-2 years. Additionally, baseline and periodic assessment of anthropometric indicators, biochemical markers, and clinical evaluation should be established. DEXA scanning can help to detect sarcopenia, which is possible even in patients with obesity. It can be caused by the nutritional deficits seen in patients with EPI and is associated with increased adverse outcomes and physical disability. The AGA also notes that other muscle mass and function tests can be considered as well. Learn more about the management of patients with EPI.